Under a new licensing deal with CureVac, GSK will acquire full rights to develop, manufacture and commercialize internationally messenger RNA, or mRNA, candidate vaccines for influenza and Covid-19.
Read Also
- Community marks 20 years since disappearance of Tamra Keepness, last seen in Regina
- Rogers lacked protections, redundencies that may have prevented 2022 outage: report
- Tesla shares wipe out loss for the year with 27% rally this week
- Slovakia's prime minister makes 1st public appearance since assassination attempt
- 5-year-old boy drowns at Wetaskiwin campground
- Brad Lambert and Colby Barlow take leading roles at Winnipeg Jets development camp
- Hamilton councillors poised to clash over calls to ban encampments in some parks
- Biden vows ‘I’m staying in the race’ as scrutiny grows on his campaign
- McKinsey Beats Back Jay Alix's Bankruptcy Racketeering Lawsuit
- More than 10,000 sea turtle eggs were rescued from Mexico’s beach ahead of Hurricane Beryl
Latest The Wall Street Journal
- McKinsey Beats Back Jay Alix's Bankruptcy Racketeering Lawsuit
- Corrections & Amplifications
- How DEI Becomes Discrimination
- The Score: Tesla, Chewy, Paramount and More Stocks That Defined the Week
- Connecticut Democrats Try to Tax the Wealthy Away
- The Campus Review: Grading an Upstate Art Outpost
- Nasdaq, S&P 500 Extend Record Run After Jobs Report
- This Chic Lakeside Retreat's Secret? It Looks Totally Custom, But Is Filled With Off-the-Rack Decor
- 14 Books We Read This Week
- Chuck D (Saturday Crossword, July 6)